Press Releases on April 11, 2024 - EIN Presswire - Press Release Distribution Service

Published on April 11, 2024 - 16:32 GMT

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

At the time of designation, the number of patients at risk of scarring post glaucoma filtration surgery was estimated to be less than 3 in 10,000 people in the European Union (EU)*. This is equivalent to a total of fewer than 152,000 people, and is below …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:32 GMT

Orphan designation: Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate ...

At the time of designation, MELAS affected less than 0.5 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 26,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:32 GMT

Investigation Into Globe Life Inc. (GL) Announced by Holzer & Holzer, LLC

ATLANTA, April 11, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Globe Life Inc. (“Globe Life” or the “Company”) (NYSE: GL) complied with federal securities laws. On April 11, 2024, Fuzzy Panda Research published a report …

Distribution channels: Consumer Goods, Law ...

Published on April 11, 2024 - 16:32 GMT

Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of ...

Neurofibromatosis type 1 is an inherited disease in which the patient develops benign (non-cancerous) tumours along the nerves. The severity of the disease varies from patient to patient, and symptoms include pale, coffee-coloured patches, freckles in …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:32 GMT

Orphan designation: Upifitamab rilsodotin Treatment of ovarian cancer, 09/12/2022 Positive

Overview This medicine was designated as an orphan medicine for the treatment of ovarian cancer in the European Union on 9 December 2022. This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:32 GMT

Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

At the time of designation, AML affected approximately 1.6 in 10,000 people in the European Union (EU). This was equivalent to a total of around 83,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:32 GMT

Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

At the time of designation, CTCL affected less than 2 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 103,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:32 GMT

Orphan designation: (S)-8-{2-amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]...

At the time of designation, pulmonary arterial hypertension affected less than 2 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 103,000 people*, and is below the ceiling for orphan designation, which is 5 people …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:32 GMT

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

At the time of designation, epidermolysis bullosa affected approximately 0.25 in 10,000 people in the European Union (EU). This was equivalent to a total of around 13,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000 …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:32 GMT

Orphan designation: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-paromamine sulfate Treatment of ...

At the time of designation, MPS I affected approximately 0.02 in 10,000 people in the European Union (EU). This was equivalent to a total of around 1,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:32 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Bosulif, Bosutinib, decision type: PM: decision on the application for ...

P/0336/2023 : EMA decision of 7 August 2023 on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (Bosulif), (EMEA-000727-PIP01-09-M07) First published: 11/04/2024Last updated: 11/04/2024Reference Number: EMA/351976/ …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on April 11, 2024 - 16:31 GMT

Vermont Allocates Moose Hunting Permits for 2024

The Vermont Fish and Wildlife Board voted on April 10 to have 80 either-sex moose hunting permits and 100 antlerless moose hunting permits available this year for a hunt limited to Vermont’s Wildlife Management Unit (WMU) E in the northeastern corner of …

Distribution channels:

Published on April 11, 2024 - 16:31 GMT

California Seizes Illegal Cannabis Products Worth $53 Million in Just 3 Months

WHAT YOU NEED TO KNOW: In the first quarter of 2024, the Governor’s Unified Cannabis Enforcement Taskforce seized over $53 million in illegal cannabis products. Authorities seized nearly 32,000 pounds of unlicensed cannabis and eradicated 54,000 illegal …

Distribution channels:

Published on April 11, 2024 - 16:30 GMT

[Latest] Global Intelligent Power Module (IPM) Market Size/Share Worth USD 4.5 Billion by 2033 at a 7.8% CAGR: Custom Market ...

Austin, TX, USA, April 11, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Intelligent Power Module (IPM) Market Size, Trends and Insights By Power Device (Insulated-Gate Bipolar Transistor (IGBT), Metal-Oxide- …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on April 11, 2024 - 16:30 GMT

Modular Trailer Market Forecasted to Reach US$ 16.2 Billion by 2034 with 5.4% CAGR Growth | Future Market Insights, Inc.

NEWARK, Del, April 11, 2024 (GLOBE NEWSWIRE) -- The modular trailer market is estimated to be worth US$ 9.6 billion in 2024 and is projected to be valued at US$ 16.2 billion by 2034. Between 2024 and 2034, the industry is expected to register a CAGR of 5. …

Distribution channels: Book Publishing Industry ...

Published on April 11, 2024 - 16:28 GMT

DEADLINE ALERT for IRBT, AVXL, INVZ, Next Bridge Hydrocarbons: Law Offices of Howard G. Smith Reminds Investors of Class Actions ...

BENSALEM, Pa., April 11, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed …

Distribution channels: Consumer Goods, Law ...

Published on April 11, 2024 - 16:27 GMT

Introducing the Inaugural Sonny Meraban Scholarship for Entrepreneurs: Fueling Tomorrow's Visionaries

MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Aspiring entrepreneurs with a keen eye for innovation and a drive to make a difference are invited to apply for the prestigious Sonny Meraban Scholarship for Entrepreneurs. Established by renowned real estate …

Distribution channels: Consumer Goods, Media, Advertising & PR ...

Published on April 11, 2024 - 16:26 GMT

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amplitude, Inc. (AMPL)

LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 15, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise …

Distribution channels: Consumer Goods, Law ...

Published on April 11, 2024 - 16:25 GMT

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against The Chemours Company (CC)

LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 20, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise …

Distribution channels: Consumer Goods, Law ...

Published on April 11, 2024 - 16:24 GMT

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Luna Innovations ...

LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 31, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise …

Distribution channels: Consumer Goods, Law ...